Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead the U.S. market for CGMs, agreed on Dec. 20 to resolve all outstanding patent disputes and not sue each other over patents for 10 years.
In a December securities filing, Dexcom said both companies agreed to provide global, non-exclusive licenses to certain patents related to analyte sensing. The agreement does not include royalties or other payments.
Abbott said in a Dec. 23 statement that the agreement is “a positive development, as it allows the company to fully focus on supporting people with diabetes with its technologies and services.” The company added that details of the settlement are confidential.
Dexcom and Abbott previously reached a settlement in 2014 related to their diabetes devices, which included a cross-licensing deal and an agreement not to sue each other until 2021. After that agreement expired, the companies filed a volley of patent lawsuits.
In March 2024, a jury found that Dexcom’s G6 glucose monitors infringed one of three of Abbott’s patents, but jurors couldn’t reach a verdict on a fourth patent.
